<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512795</url>
  </required_header>
  <id_info>
    <org_study_id>BLOT AOI 2017</org_study_id>
    <nct_id>NCT03512795</nct_id>
  </id_info>
  <brief_title>Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations</brief_title>
  <acronym>Mutapro</acronym>
  <official_title>Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The analysis of HIV resistance to antiretrovirals (Sanger sequencing on RNA) is difficult&#xD;
      when the viral load is undetectable or during therapeutic breaks. In these situations, the&#xD;
      ultra-deep sequencing (UDS) can be done on proviral DNA in order to improve characterization&#xD;
      of archived resistant variants with may reflect past virological failures.&#xD;
&#xD;
      This study is a cross-sectional study which will require only one additional tube which can&#xD;
      be taken during a routine check-up as part of the usual follow-up of the individuals&#xD;
      included.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>&gt; Genotyping Score (GSS) comparison between HIV DNA-UDS genotyping assay obtained at inclusion and cumulative RNA-Sanger genotyping assays obtained at each virological failure during routine follow</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">98</enrollment>
  <condition>HIV-1-infection</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>An additional blood tube will be taken during the patient's follow-up blood collection.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients living with HIV-1, with an undetectable viral load and a history of at least 2&#xD;
        virological failures in which resistance to at least two drug classes was observed&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who has given consent&#xD;
&#xD;
          -  Adult patient&#xD;
&#xD;
          -  Patient living with HIV-1&#xD;
&#xD;
          -  Controlled viral load (&lt;50 RNA copies/ml) for at least 1 year.&#xD;
&#xD;
          -  At least two previous virologic failures, either :&#xD;
&#xD;
               -  Initial failure : defined as the persistence of a viral load greater than 50&#xD;
                  copies/ml beyond 1 year, after the initiation of triple antiretroviral therapy,&#xD;
                  and without virological control (VL &gt; 50 copies/ml) since the initiation of the&#xD;
                  very first antiretroviral treatment.&#xD;
&#xD;
               -  A rebound in HIV viral load to more than 50 copies/ml after a period of&#xD;
                  virological success, confirmed on two consecutive samples at least one month&#xD;
                  apart.&#xD;
&#xD;
          -  At least 2 Sanger RNA genotypes have been done or could be done from the existing&#xD;
             library.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient not affiliated to a medical insurance scheme&#xD;
&#xD;
          -  Protected adult&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding woman&#xD;
&#xD;
          -  Discontinuation of clinical and immuno-virological follow-up for more than 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathieu BLOT</last_name>
    <phone>03.80.29.33.05</phone>
    <email>mathieu.blot@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu BLOT</last_name>
      <phone>03.80.29.33.05</phone>
      <email>mathieu.blot@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2018</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

